Ultragenyx Pharmaceutical - RARE Stock Forecast, Price & News

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last twelve months. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RARE shares.
View RARE analyst ratings or view top-rated stocks.

11 brokers have issued 1-year price objectives for Ultragenyx Pharmaceutical's stock. Their RARE share price forecasts range from $50.00 to $142.00. On average, they predict the company's stock price to reach $88.67 in the next twelve months. This suggests a possible upside of 135.3% from the stock's current price.
View analysts price targets for RARE or view top-rated stocks among Wall Street analysts.

Ultragenyx Pharmaceutical's stock was trading at $46.33 at the beginning of 2023. Since then, RARE stock has decreased by 18.7% and is now trading at $37.68.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our RARE earnings forecast.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) issued its quarterly earnings results on Thursday, February, 16th. The biopharmaceutical company reported ($2.16) EPS for the quarter, missing analysts' consensus estimates of ($2.03) by $0.13. The biopharmaceutical company had revenue of $103.35 million for the quarter, compared to the consensus estimate of $105.11 million. Ultragenyx Pharmaceutical had a negative net margin of 194.71% and a negative trailing twelve-month return on equity of 110.15%. The firm's revenue for the quarter was up 23.9% on a year-over-year basis. During the same quarter last year, the company earned ($1.79) earnings per share.

ETFs with the largest weight of Ultragenyx Pharmaceutical (NASDAQ:RARE) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), First Trust NYSE Arca Biotechnology Index Fund (FBT), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Products ETF (BBP), Motley Fool Small-Cap Growth ETF (TMFS), MFAM Small-Cap Growth ETF (MFMS), SPDR S&P Biotech ETF (XBI) and Principal Healthcare Innovators ETF (BTEC).

Ultragenyx Pharmaceutical updated its FY 2023 earnings guidance on Monday, February, 20th. The company provided EPS guidance of for the period. The company issued revenue guidance of $425.00 million-$450.00 million, compared to the consensus revenue estimate of $432.78 million.

41 employees have rated Ultragenyx Pharmaceutical Chief Executive Officer Emil D. Kakkis on Glassdoor.com. Emil D. Kakkis has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Pfizer (PFE), AbbVie (ABBV), NVIDIA (NVDA), Exelixis (EXEL), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), TG Therapeutics (TGTX), GW Pharmaceuticals (GWPH) and QUALCOMM (QCOM).

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

Ultragenyx Pharmaceutical's stock is owned by many different retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (5.84%), Avidity Partners Management LP (4.26%), Clearbridge Investments LLC (3.84%), Alkeon Capital Management LLC (2.65%), Alliancebernstein L.P. (2.20%) and First Trust Advisors LP (1.63%). Insiders that own company stock include Camille L Bedrosian, Camille L Bedrosian, Clay B Siegall, Dennis Karl Huang, Emil D Kakkis, Emil D Kakkis, Erik Harris, John Richard Pinion, Karah Herdman Parschauer, Mardi Dier, Matthew K Fust, S Robson Walton, Shalini Sharp, Theodore Alan Huizenga, Thomas Richard Kassberg and William Aliski.
View institutional ownership trends.

Shares of RARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RARE stock can currently be purchased for approximately $37.68.

Ultragenyx Pharmaceutical (NASDAQ:RARE) has a market capitalization of $2.65 billion and generates $363.33 million in revenue each year. The biopharmaceutical company earns $-707,420,000.00 in net income (profit) each year or ($10.11) on an earnings per share basis.

The company employs 1,311 workers across the globe.

Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The official website for the company is www.ultragenyx.com. The biopharmaceutical company can be reached via phone at (415) 483-8800, via email at ir@ultragenyx.com, or via fax at 415-483-8810.